Search results for "LIPOPROTEIN"

showing 10 items of 982 documents

The association between Mediterranean Diet Score and glucokinase regulatory protein gene variation on the markers of cardiometabolic risk: an analysi…

2014

Consumption of a Mediterranean diet (MD) and genetic variation in the glucokinase regulatory protein (GCKR) gene have been reported to be associated with TAG and glucose metabolism. It is uncertain whether there is any interaction between these factors. Therefore, the aims of the present study were to test the association of adherence to a MD and rs780094 (G>A) SNP in theGCKRgene with the markers of cardiometabolic risk, and to investigate the interaction between genetic variation and MD adherence. We studied 20 986 individuals from the European Prospective Investigation into Cancer (EPIC)-Norfolk study. The relative Mediterranean Diet Score (rMED: range 0–18) was used to assess MD adher…

OncologyMaleMediterranean dietMedicine (miscellaneous)030204 cardiovascular system & hematologyDiet MediterraneanCohort Studies0302 clinical medicineGenotype030212 general & internal medicineProspective StudiesGene–environment interactionProspective cohort studyNutrition and DieteticsGlucokinase regulatory proteinConfoundingDietary Surveys and Nutritional EpidemiologyMiddle AgedFull PapersLipids3. Good healthEnglandCardiovascular DiseasesFemaleAdultRiskmedicine.medical_specialtyBiologyPolymorphism Single Nucleotide03 medical and health sciencesInternal medicineMediterranean dietGenetic variationmedicineSNPHumansGenetic Association StudiesAdaptor Proteins Signal TransducingAgedGlycated HemoglobinCardiometabolic riskEndocrinologyCross-Sectional StudiesApolipoproteinsDiabetes Mellitus Type 2biology.proteinPatient ComplianceGene-Environment InteractionGlucokinase regulatory proteinBiomarkersThe British journal of nutrition
researchProduct

The Effects of Tamoxifen on Plasma Lipoprotein(a) Concentrations: Systematic Review and Meta-Analysis

2017

Introduction: Tamoxifen is a selective estrogen receptor modulator widely used in the treatment of breast cancer. Tamoxifen therapy is associated with reduced circulating low-density lipoprotein cholesterol and increased triglycerides, but its effects on other lipids are less-well studied. Aims: We aimed to investigate the effect of tamoxifen on circulating concentrations of lipoprotein(a) (Lp(a)) through systematic review and meta-analysis of available randomized controlled trials (RCTs) and observational studies. Methods: This study was registered in the PROSPERO database (CRD42016036890). Scopus, Medline and EMBASE were searched from inception until 22nd March 2016 to identify studies in…

OncologySelective Estrogen Receptor Modulatorsmedicine.medical_specialtyRMTamoxifen; lipoprotein(a) concentration; circulation; treatmentBreast Neoplasms030204 cardiovascular system & hematologylaw.invention03 medical and health sciences0302 clinical medicineBreast cancerRandomized controlled triallawInternal medicineCell Line TumormedicineHumansPharmacology (medical)QDRandomized Controlled Trials as Topictreatmentbusiness.industrymedicine.diseaselipoprotein(a) concentrationConfidence intervalTamoxifenEndocrinologyStrictly standardized mean differenceSelective estrogen receptor modulator030220 oncology & carcinogenesisMeta-analysiscirculationFemaleSystematic ReviewbusinessTamoxifenmedicine.drugLipoproteinLipoprotein(a)
researchProduct

Diabetes and Colorectal Cancer Risk: A New Look at Molecular Mechanisms and Potential Role of Novel Antidiabetic Agents.

2021

Epidemiological data have demonstrated a significant association between the presence of type 2 diabetes mellitus (T2DM) and the development of colorectal cancer (CRC). Chronic hyperglycemia, insulin resistance, oxidative stress, and inflammation, the processes inherent to T2DM, also play active roles in the onset and progression of CRC. Recently, small dense low-density lipoprotein (LDL) particles, a typical characteristic of diabetic dyslipidemia, emerged as another possible underlying link between T2DM and CRC. Growing evidence suggests that antidiabetic medications may have beneficial effects in CRC prevention. According to findings from a limited number of preclinical and clinical stud…

Oncologyendocrine system diseasesColorectal cancerComorbidityReview0302 clinical medicineinsulin resistanceEpidemiologyBiology (General)small dense LDLSpectroscopyglucagon-like peptide-1 receptor agonists0303 health sciencesIncidenceGeneral MedicineSmall dense LDL3. Good healthComputer Science ApplicationsLipoproteins LDLChemistry030220 oncology & carcinogenesismedicine.symptomColorectal Neoplasmsmedicine.medical_specialtyQH301-705.5InflammationCatalysisGlucagon-like peptide-1 receptor agonistsGlucagon-Like Peptide-1 ReceptorInorganic Chemistry03 medical and health sciencesInsulin resistanceInternal medicineDiabetes mellitusmedicineHumansHypoglycemic AgentsIn patientPhysical and Theoretical ChemistryQD1-999Molecular BiologyAntidiabetic agents030304 developmental biologyInflammationbusiness.industryOrganic ChemistryType 2 Diabetes Mellitusnutritional and metabolic diseasesInsulin resistanceGlucagon-like peptide-1 receptor agonists Hyperglycemia Inflammation Insulin resistance Comorbidity Diabetes Mellitus Type 2 Glucagon-Like Peptide-1 Receptor Humans Hyperglycemia Hypoglycemic Agents Incidence Lipoproteins LDL Oxidative Stress Colorectal Neoplasms Small dense LDLmedicine.diseasedigestive system diseasesOxidative StressDiabetes Mellitus Type 2Oxidative stressinflammationHyperglycemiabusinessInternational journal of molecular sciences
researchProduct

Lipoprotein(a) – Marker for cardiovascular risk and target for lipoprotein apheresis

2019

Lipoprotein(a) (Lp(a)) consists of an LDL particle whose apolipoprotein B (apoB) is covalently bound to apolipoprotein(a) (apo[a]). An increased Lp(a) concentration is a causal, independent risk factor for atherosclerotic cardiovascular disease (ASCVD) and a predictor of incident or recurrent cardiovascular events. Although Lp(a) was first described as early as 1963, only the more recent results of epidemiological, molecular, and genetic studies have led to this unequivocal conclusion. More than 20% of Western populations have elevated Lp(a) values. Lp(a) concentrations should be always part of the lipid profile when ASCVD risk is assessed. However, presence of other risk factors, laborator…

Oncologymedicine.medical_specialtyApolipoprotein B030204 cardiovascular system & hematologyRisk Assessment03 medical and health scienceschemistry.chemical_compound0302 clinical medicineGermanyInternal medicineInternal MedicineHumansMedicineMedical history030212 general & internal medicineFamily historyRisk factorbiologymedicine.diagnostic_testbusiness.industryCholesterolPatient SelectionGeneral MedicineLipoprotein(a)AtherosclerosischemistryCardiovascular DiseasesBlood Component Removalbiology.proteinlipids (amino acids peptides and proteins)Cardiology and Cardiovascular MedicinebusinessLipid profileBiomarkersLipoprotein(a)LipoproteinAtherosclerosis Supplements
researchProduct

Enhanced susceptibility of cholesteryl sulfate-enriched low density lipoproteins to copper-mediated oxidation

1995

AbstractCholesteryl sulfate (CS) is a minor component of cell membranes, also present in lipoproteins, and its exact function is unknown. Since oxidation of low density lipoproteins (LDL) is thought to be an important determinant of atherogenesis, we investigated the influence of CS enrichment on copper-mediated oxidation of LDL. CS was found to act as a pro-oxidant, as measured by lipid oxidation parameters. The results also suggest that these effects were dependent on the sulfate group since pure cholesterol or cholesteryl acetate did not promote Cu2+-mediated oxidation. Our findings imply that CS may affect the oxidizability and hence the potential atherogenicity of LDL.

Oxidized LDLArteriosclerosisBiophysicschemistry.chemical_elementCholesteryl sulfateCholesteryl sulfateBiochemistryThiobarbituric Acid Reactive Substanceschemistry.chemical_compoundStructure-Activity RelationshipLipid oxidationStructural BiologyCholesterylester transfer proteinOxidationGeneticsHumansSulfateMolecular BiologyIntermediate-density lipoproteinbiologyCholesterolCell BiologyCopperLipoproteins LDLMembranechemistryBiochemistrybiology.proteinlipids (amino acids peptides and proteins)Cholesterol EstersLipid PeroxidationCopperFEBS Letters
researchProduct

Pro-oxidant effects of 7-hydroperoxycholest-5-en-3β-ol on the copper-initiated oxidation of low density lipoprotein

1995

AbstractIn low density lipoproteins (LDL) supplemented with aged cholesterol and oxidized in the presence of Cu2+, an increase of the lipid oxidation parameters was observed compared with pure cholesterol-enriched LDL. A compound, identified as 7-hydroperoxycholesterol (7HPC), isolated from aged cholesterol and added to LDL, reproduced the above effects. The results indicate that the pro-oxidant effect of 7HPC is dependent on the hydroperoxy group since the corresponding alcohol derivative, 7α-hydroxycholesterol, had no such effect. These data suggest that among the LDL-associated lipid peroxides, cholesterol peroxides may have important implications in the susceptibility of this lipoprotei…

Oxidized LDLLipid PeroxidesVery low-density lipoproteinTime FactorsOxysterolBiophysicsBiochemistryMedicinal chemistrychemistry.chemical_compoundOxysterolLipid oxidationStructural BiologyOxidationGeneticsHumansMolecular BiologyIntermediate-density lipoproteinCholesterolCell BiologyOxidantsPro-oxidantLipoproteins LDLCholesterolchemistryLow-density lipoproteinCholesterol hydroperoxidelipids (amino acids peptides and proteins)Oxidation-ReductionAged cholesterolCopperLipoproteinFEBS Letters
researchProduct

Lipid rafts: a signalling platform linking lipoprotein metabolism to atherogenesis.

2012

Lipid rafts are microdomains of the plasma membrane which are enriched in cholesterol and sphingolipids. They serve as a platform for signal transduction, in particular during immune and inflammatory responses. As hypercholesterolemia and inflammation are two key elements of atherogenesis, it is conceivable that the cholesterol and cholesterol oxide content of lipid rafts might influence the inflammatory signalling pathways, thus modulating the development of atherosclerosis. In support of this emerging view, lipid rafts have been shown to be involved in several key steps of atherogenesis, such as the oxysterol-mediated apoptosis of vascular cells, the blunted ability of high density lipopr…

OxysterolCholesterolLipoproteinsInflammationAtherosclerosisSphingolipidCell biologychemistry.chemical_compoundCholesterolMembrane MicrodomainschemistryLipid dropletmedicineAnimalsBlood VesselsHumanslipids (amino acids peptides and proteins)Signal transductionmedicine.symptomInflammation MediatorsCardiology and Cardiovascular MedicineLipid raftLipoproteinSignal TransductionAtherosclerosis
researchProduct

Pooling and expanding registries of familial hypercholesterolaemia to assess gaps in care and improve disease management and outcomes: Rationale and …

2016

WOS: 000393031600001

PREDICTIONInternational CooperationPoolingInformation Storage and RetrievalDisease030204 cardiovascular system & hematologyGUIDELINESDoenças Cardio e Cérebro-vascularesLDL-Cholesterol0302 clinical medicineCardiovascular DiseaseMedicineData MiningCardiac and Cardiovascular Systems030212 general & internal medicineRegistriesDisease management (health)Cooperative BehaviorGENERAL-POPULATIONRISKFamilial hypercholesterolaemia ; LDL-Cholesterol ; Cardiovascular disease ; RegistryKardiologiCONSENSUS PANELDelivery of Health Care IntegratedGeneral MedicineOrvostudományokCardiovascular diseasePREVALENCE3. Good healthTreatment OutcomeCARDIOVASCULAR-DISEASEResearch DesignFamilial hypercholesterolaemiaCardiology and Cardiovascular MedicineRegistrymedicine.medical_specialtyBest practiceKlinikai orvostudományokAccess to InformationHyperlipoproteinemia Type II03 medical and health sciencesEUROPEAN ATHEROSCLEROSIS SOCIETYInternal MedicineHumansOrganizational ObjectivesBespokeStudy DesignGUIDANCEbusiness.industryPublic healthStudy designProfessional Practice GapsData sharingClinical trialCardiovascular System & Hematology3121 General medicine internal medicine and other clinical medicineFamily medicineFamilial hypercholesterolaemia; LDL-Cholesterol; Cardiovascular disease; Registry; Study design; Familial Hypercholesterolaemia Studies CollaborationFamilial Hypercholesterolaemia Studies CollaborationFamilial HypercholesterolaemiaINDIVIDUAL PARTICIPANT DATAbusiness
researchProduct

Familial hypercholesterolaemia: A global call to arms

2015

Familial Hypercholesterolaemia (FH) is the commonest autosomal co-dominantly inherited condition affecting man. It is caused by mutation in one of three genes, encoding the low-density lipoprotein (LDL) receptor, or the gene for apolipoprotein B (which is the major protein component of the LDL particle), or in the gene coding for PCSK9 (which is involved in the degradation of the LDL-receptor during its cellular recycling). These mutations result in impaired LDL metabolism, leading to life-long elevations in LDL-cholesterol (LDL-C) and development of premature atherosclerotic cardiovascular disease (ASCVD) [1], [2] and [3]. If left untreated, the relative risk of premature coronary artery d…

PathologyApolipoprotein BDisease030204 cardiovascular system & hematologymedicine.disease_causeGlobal HealthDISEASEDoenças Cardio e Cérebro-vasculares0302 clinical medicineHyperlipoproteinemia Type IISocieties MedicalRISK0303 health sciencesMutationbiology3. Good healthPREVALENCEEuropelipids (amino acids peptides and proteins)Cardiology and Cardiovascular MedicineFamilial hypercholesterolaemiaLife Sciences & Biomedicinemedicine.medical_specialtyHeterozygote1102 Cardiovascular Medicine And HaematologyHyperlipoproteinemia Type II03 medical and health sciencesInternal medicinemedicineHumans030304 developmental biologyScience & Technologybusiness.industryGUIDANCEPCSK9Heterozygote advantage1103 Clinical SciencesEndocrinologyPeripheral Vascular DiseaseCardiovascular System & HematologyReceptors LDLRECEPTORES DE LIPOPROTEÍNASRelative riskMutationbiology.proteinCardiovascular System & CardiologyFamilial HypercholesterolaemiabusinessCLINICIANLipoprotein
researchProduct

A proposal to redefine familial combined hyperlipidaemia -- third workshop on FCHL held in Barcelona from 3 to 5 May 2001, during the scientific sess…

2002

Item does not contain fulltext

Pathologymedicine.medical_specialtyLipoproteins and atheroscleroseApolipoprotein Bbiologybusiness.industryClinical BiochemistryGeneral MedicineApolipoproteins bLipoproteïnen en atherosclerose030204 cardiovascular system & hematologyBiochemistryCoronary heart disease03 medical and health sciences0302 clinical medicineClinical investigationInternal medicinebiology.proteinMedicine030212 general & internal medicineFamilial combined hyperlipidaemiabusiness
researchProduct